Today: 20 May 2026
Browse Category

NASDAQ:AVDL 22 October 2025

Avadel Stock Rockets on $2.1B Alkermes Buyout Offer – Key Developments & Analyst Takeaways

Avadel Stock Rockets on $2.1B Alkermes Buyout Offer – Key Developments & Analyst Takeaways

Alkermes will acquire Avadel for $18.50 per share in cash, plus a $1.50 contingent payout, valuing the deal at about $2.1 billion. Avadel’s LUMRYZ sales are projected at $265–$275 million in 2025, with 3,100 patients on therapy. AVDL shares surged to near a 52-week high after the Jazz settlement and Alkermes news. Halper Sadeh LLC is investigating whether the offer undervalues Avadel.
22 October 2025
·····

Stock Market Today

  • Stock Market Continues Modest Pullback as Leading Growth Stocks Hold
    May 19, 2026, 7:45 PM EDT. The stock market extended its losing streak to three sessions on Tuesday, marking a modest and orderly pullback. Despite the slump, leading growth stocks demonstrated resilience, showing signs of underlying strength amid broader market pressure. Investors are watching carefully as the overall market digests recent gains, while specific oil and gas companies attract attention for potential opportunities. This cautious environment suggests investors are balancing profit-taking with selective buying in sectors showing robust performance.

Latest articles

GCL Global Stock’s Wild After-Hours Jump: The $10 Million ADATA Deal Behind the Move

GCL Global Stock’s Wild After-Hours Jump: The $10 Million ADATA Deal Behind the Move

20 May 2026
GCL Global Holdings shares jumped to $1.00 after hours Tuesday, up 132%, following news that ADATA Technology invested another $10 million in its 4Divinity unit. The stock had closed regular trading at $0.43, below Nasdaq’s $1 minimum. Recent filings still warn of listing and execution risks. GCL reported first-half revenue up 94% to $98.7 million but posted a net loss of $5.6 million.
James Hardie Drops After Warning on Housing, Even With Q4 Beat

James Hardie Drops After Warning on Housing, Even With Q4 Beat

20 May 2026
James Hardie’s U.S.-listed shares dropped 6.1% Tuesday and slid another 2.6% after hours after reporting a 35% fall in quarterly net income to $28.5 million, despite a 45% jump in net sales to $1.40 billion. The company cited weak housing demand and warned the market remains uncertain. ASX shares had not traded post-earnings; they last closed at A$26.78, up 2.9%.
SELLAS Stock Jumps as One Trial Number Puts Cancer Readout in Focus

SELLAS Stock Jumps as One Trial Number Puts Cancer Readout in Focus

20 May 2026
SELLAS Life Sciences shares rose 4.1% to $7.59 Tuesday after CEO Angelos Stergiou said its Phase 3 AML trial is two events from final analysis. The company reported $107.1 million in cash and a first-quarter net loss of $8.4 million. The REGAL trial’s main measure is overall survival. SELLAS remains blinded to results until the 80th event triggers data review.
Go toTop